ImmuCell

ICCC

Market cap $54.6M

CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.

PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense ® product line and away from Re-Tain ® on December 24, 2025.

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain ® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense ® field sales force by 50% and expanding its First Defense ® manufacturing capabilities.

ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.

ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.

ImmuCell Corporation ( ICCC ) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Company Participants Michael Brigham - Special Advisor to the CEO & Director P. F. Te Boekhorst - President, CEO & Director Timothy Fiori - CFO, Secretary, Treasurer & Director Conference Call Participants Joe Diaz - Lytham Partners, LLC Frank Gasca George Melas - MKH Management Company, LLC Presentation Operator Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited Financial Results Conference Call.

PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025.

PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results.